Based on the results from the LINKER-MM1 study, can you provide insights into the overall efficacy of linvoseltamab in patients with relapsed/refractory multiple myeloma? What response rates and outcomes have been observed?

The study indicates that responses to linvoseltamab deepen over time. Could you elaborate on the response patterns observed in patients and the implications for long-term treatment efficacy?

What is the safety profile of linvoseltamab, particularly in terms of treatment-emergent adverse events? How manageable are the observed adverse events, and are there any specific safety concerns that stand out?

Were there any notable findings in subgroup analyses, such as patients with triple-class refractory disease, older patients, or those with high cytogenetic risk? How does linvoseltamab perform in these challenging patient populations?

Could you discuss the duration of response observed with linvoseltamab treatment and its impact on progression-free survival in RRMM patients?

The study mentions improvements in patient-reported outcomes (PRO) in terms of quality of life and pain symptoms. How significant are these improvements in enhancing the overall well-being of RRMM patients?

The study mentions CRS as a common treatment-emergent adverse event. Can you elaborate on the management and significance of CRS in linvoseltamab-treated patients? Additionally, how does the rate of infections, including COVID-19, impact patient care?

In light of the promising results from the LINKER-MM1 study, what are the potential future implications of linvoseltamab in the management of RRMM? How might this therapy fit into the evolving landscape of multiple myeloma treatment?